The role of microbiota in nonalcoholic fatty liver disease.
Eur J Clin Invest
; 52(7): e13768, 2022 Jul.
Article
en En
| MEDLINE
| ID: mdl-35294774
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is the most frequent liver disease worldwide. Gut microbiota can play a role in the pathogenesis of NAFLD since dysbiosis is associated with reduced bacterial diversity, altered Firmicutes/Bacteroidetes ratio, a relative abundance of alcohol-producing bacteria, or other specific genera. Changes can promote disrupted intestinal barrier and hyperpermeability, filtration of bacterial products, activation of the immune system, and pro-inflammatory changes in the intestine, in the liver, and at a systemic level. Microbiota-derived molecules can contribute to the steatogenic effects. The link between gut dysbiosis and NAFLD, however, is confused by several factors which include age, BMI, comorbidities, dietary components, and lifestyle. The role of toxic chemicals in food and water requires further studies in both gut dysbiosis and NAFLD. We can anticipate that gut microbiota manipulation will represent a potential therapeutic tool to delay or reverse the progression of NAFLD, paving the way to primary prevention measures.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Microbiota
/
Enfermedad del Hígado Graso no Alcohólico
/
Microbioma Gastrointestinal
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Revista:
Eur J Clin Invest
Año:
2022
Tipo del documento:
Article
País de afiliación:
Italia